76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Aclaris Therapeutics Inc
Closed
1.53 -1.29
Overview
Share price change
24h
Min
1.52
Max
1.64
Income | 81M -15M |
|---|---|
Sales | -7.8M 1.5M |
EPS | -0.12 |
Profit margin | -1,036.77 |
Employees | 61 |
EBITDA | -4.2M -18M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +505.59% upside |
Next Earnings | 6 Aug 2025 |
|---|
Market Cap | 17M 156M |
|---|---|
Previous open | 2.82 |
Previous close | 1.53 |
Technical Score
By Trading Central
Confidence
Weak Bullish Evidence
Aclaris Therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Aclaris Therapeutics Inc Forecast
Price Target
By TipRanks
505.59% upside
12 Months Forecast
Average 9.75 USD 505.59%
High 16 USD
Low 7 USD
Based on 5 Wall Street analysts offering 12 month price targets forAclaris Therapeutics Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Aclaris Therapeutics Inc
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
